Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
Respectable revenue fueled to reduce losess, at Adma Biologics Inc amid the financial fourth quarter of 2022
Adma Biologics Inc reported fourth quarter of 2022 operating deficit of $-6.058542 million
Published Mar 24 2023
CSIMarket Team / CSIMarket.com
Conflicting to the Q3 revenue improved by 21.639 % from $41.09 million and EPS improved from $-0.08 per share.
In the fiscal span closing December 31 2022 Adma Biologics Inc reported net loss of $-12.232 million, instead of deficit of $-16.649 million in the corresponding reporting season a year ago.
What's more important, the company claimed as well a shortfall of $-65.90 million and for the financial year 2022, revenue of $154.08 million.
Biotechnology & Pharmaceuticals The company has decreased it's loss per share to $-0.33 from $-0.51 in the previous fiscal year, while revenue surged by 90.36 % from $80.94 million a year before.
Adma Biologics Inc is expected to report next financial earnings on May 10, 2023.
Other ADMA's news
Adma Biologics Inc Sees Enlarged Diminishing Returns in Fourth Quarter Financial Report
Adma Biologics Inc Witnesses Impressive 62.211% Revenue Surge in Recent Fiscal Period
Adma Biologics Inc Shines with an Impressive 76.051% Revenue Jump in Latest Fiscal Period
Respectable Revenue Surprisingly Mitigates Loses at Adma Biologics Inc in Q1 2023
Very impressive 98.69%, jump in Revenues at in the fiscal three months closing Sep 30 2022
Other ADMA's news
Adma Biologics Inc Sees Enlarged Diminishing Returns in Fourth Quarter Financial Report
Adma Biologics Inc Witnesses Impressive 62.211% Revenue Surge in Recent Fiscal Period
Adma Biologics Inc Shines with an Impressive 76.051% Revenue Jump in Latest Fiscal Period
Respectable Revenue Surprisingly Mitigates Loses at Adma Biologics Inc in Q1 2023
Very impressive 98.69%, jump in Revenues at in the fiscal three months closing Sep 30 2022